Siegfried, a global contract development and manufacturing organization (CDMO) headquartered in Zofingen, Switzerland, has signed agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, WI.

The new site, which specializes in early-phase development and manufacturing services with a team of more than 80 employees, is set to strengthen Siegfried’s offering for drug substances in terms of capabilities and geographical coverage. Siegfried intends to develop the site into a best-in-class hub for early-phase CDMO services for its global customer base, including services for projects with highly potent APIs. The transaction is expected to close by July 1, 2024.

“With this acquisition, we enhance our offering with early-stage development services for drug substances and become even more relevant and attractive to our customers,” said Reto Suter, CEO ad interim and CFO of Siegfried. “Siegfried now offers an integrated range of services from early-stage development to commercial production of APIs through to the manufacturing of fully formulated drug products.”

The acquisition will strengthen Siegfried’s position in the U.S., the world’s largest pharmaceutical market, and enables Siegfried to provide comprehensive support to customers in the pre-clinical and clinical development and manufacturing of drug substances. The deal also expands Siegfried’s offering, particularly for small and medium-sized pharmaceutical companies. The focus on early-phase CDMO services will also strengthen Siegfried’s drug substance pipeline by capturing additional opportunities in their early stage, creating growth opportunities in the future.